ES2132601T3 - Procedimiento para la seleccion de bacteriofagos especificos. - Google Patents

Procedimiento para la seleccion de bacteriofagos especificos.

Info

Publication number
ES2132601T3
ES2132601T3 ES95903485T ES95903485T ES2132601T3 ES 2132601 T3 ES2132601 T3 ES 2132601T3 ES 95903485 T ES95903485 T ES 95903485T ES 95903485 T ES95903485 T ES 95903485T ES 2132601 T3 ES2132601 T3 ES 2132601T3
Authority
ES
Spain
Prior art keywords
fagus
molecula
specific
bacteriophaguses
selection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95903485T
Other languages
English (en)
Inventor
Carl A K Borrebaeck
Marta Pasaje Duenas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioinvent International AB
Original Assignee
Bioinvent International AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent International AB filed Critical Bioinvent International AB
Application granted granted Critical
Publication of ES2132601T3 publication Critical patent/ES2132601T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE PRESENTA UN METODO PARA SELECCIONAR UNA MOLECULA, TAL COMO UN ANTICUERPO, UN ANTIGENO, UN PEPTIDO, UNA PROTEINA O UN FRAGMENTO DE LA MISMA, LA MOLECULA SE EXPRESA JUNTO CON LA PROTEINA DE REVESTIMIENTO DEL FAGO SOBRE LA SUPERFICIE DEL FAGO. EL METODO SE CARACTERIZA POR UNIR LA REPLICACION DEL FAGO AL RECONOCIMIENTO DE LA MOLECULA SOBRE LA SUPERFICIE DEL FAGO. LA UNION PUEDE CONSEGUIRSE MEDIANTE EL USO DE UNA PROTEINA DE FUSION ENTRE LA PROTEINA 3 DEL FAGO Y UN LIGANTE DE UNION ESPECIFICO PARA LA MOLECULA.
ES95903485T 1993-12-06 1994-12-05 Procedimiento para la seleccion de bacteriofagos especificos. Expired - Lifetime ES2132601T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9304060A SE9304060D0 (sv) 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager

Publications (1)

Publication Number Publication Date
ES2132601T3 true ES2132601T3 (es) 1999-08-16

Family

ID=20392016

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95903485T Expired - Lifetime ES2132601T3 (es) 1993-12-06 1994-12-05 Procedimiento para la seleccion de bacteriofagos especificos.

Country Status (12)

Country Link
US (1) US5712089A (es)
EP (1) EP0739413B1 (es)
JP (1) JP3574135B2 (es)
AT (1) ATE178092T1 (es)
AU (1) AU686292B2 (es)
CA (1) CA2178205A1 (es)
DE (1) DE69417446T2 (es)
DK (1) DK0739413T3 (es)
ES (1) ES2132601T3 (es)
GR (1) GR3030210T3 (es)
SE (1) SE9304060D0 (es)
WO (1) WO1995016027A1 (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2113940T3 (es) * 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
GB9500851D0 (en) * 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
SE9503151D0 (sv) * 1995-09-13 1995-09-13 Bioinvent Internatioal Ab Combined ligand and receptor display
SE506771C2 (sv) * 1996-02-06 1998-02-09 Gotpat 105 Ab Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6497874B1 (en) 1997-02-05 2002-12-24 Maardh Sven Recombinant phages
GB9716900D0 (en) * 1997-08-08 1997-10-15 Bioinvent Int Ab Method for selecting phage displaying ligand binders
CA2320960A1 (en) * 1998-02-11 1999-08-19 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
EP1518927A3 (en) * 1998-02-11 2005-06-22 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
CA2334170A1 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
EP1240319A1 (en) * 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US6686154B2 (en) 2000-06-05 2004-02-03 Zyomyx, Inc. Screening of phage displayed peptides without clearing of the cell culture
ATE415978T1 (de) 2000-07-27 2008-12-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
CA2485506C (en) * 2002-05-17 2012-02-28 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
SI1551876T1 (sl) 2002-10-16 2011-07-29 Purdue Pharma Lp Protitelesa, ki se vežejo na celično povezan CA 125/0722P, in postopki za njihovo uporabo
GB2400851B (en) * 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP1789453A2 (en) * 2004-05-18 2007-05-30 Genentech, Inc. M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
US8198034B2 (en) 2008-03-14 2012-06-12 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
RU2010151562A (ru) 2008-06-20 2012-07-27 ВАЙЕТ ЭлЭлСи (US) Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
JP5723774B2 (ja) * 2008-09-05 2015-05-27 プレジデント アンド フェローズ オブ ハーバード カレッジ タンパク質および核酸の連続的指向性進化
WO2010105236A1 (en) 2009-03-13 2010-09-16 Allergan, Inc. Immuno-based retargeted endopeptidase activity assays
EP2609211A1 (en) * 2010-08-27 2013-07-03 University of Zurich A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
CA2825370A1 (en) * 2010-12-22 2012-06-28 President And Fellows Of Harvard College Continuous directed evolution
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
WO2014150870A2 (en) 2013-03-15 2014-09-25 Altria Client Services Inc. Bacteriophage and methods of making and using
CA2932788A1 (en) 2013-12-08 2015-06-11 Peptcell Limited Hiv antigens and antibodies and compositions, methods and uses thereof
EP4043493A1 (en) 2013-12-24 2022-08-17 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
EP3097196B1 (en) 2014-01-20 2019-09-11 President and Fellows of Harvard College Negative selection and stringency modulation in continuous evolution systems
WO2016077052A2 (en) 2014-10-22 2016-05-19 President And Fellows Of Harvard College Evolution of proteases
WO2016123425A1 (en) 2015-01-29 2016-08-04 Altria Client Services Llc Endolysin from bacteriophage against geobacillus and methods of using
WO2016123427A1 (en) 2015-01-29 2016-08-04 Altria Client Services Llc Bacteriophage and methods of using
US11299729B2 (en) 2015-04-17 2022-04-12 President And Fellows Of Harvard College Vector-based mutagenesis system
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
WO2017015545A1 (en) 2015-07-22 2017-01-26 President And Fellows Of Harvard College Evolution of site-specific recombinases
WO2017015559A2 (en) 2015-07-23 2017-01-26 President And Fellows Of Harvard College Evolution of bt toxins
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
TW202216201A (zh) 2016-02-12 2022-05-01 比利時商楊森製藥公司 抗vista抗體及片段、其用途及鑑定其之方法
EA201892190A1 (ru) 2016-03-29 2019-04-30 Янссен Байотек, Инк. Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP3519049B1 (en) 2016-09-30 2025-12-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
MX2019005661A (es) 2016-11-16 2019-10-07 Janssen Biotech Inc Método para tratar la psoriasis con el anticuerpo específico anti-il23.
JP2020506916A (ja) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
EP3579871A4 (en) 2017-02-07 2021-07-21 Janssen Biotech, Inc. ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS OF TREATMENT FOR ACTIVE BECHTEREW'S LIVER
WO2019010164A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College Evolution of trna synthetases
WO2019040935A1 (en) 2017-08-25 2019-02-28 President And Fellows Of Harvard College EVOLUTION OF PEPTIDASES BONT
WO2019056002A1 (en) 2017-09-18 2019-03-21 President And Fellows Of Harvard College CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US20190135910A1 (en) 2017-11-06 2019-05-09 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
ES3064335T3 (en) 2018-03-05 2026-04-24 Janssen Biotech Inc Methods of treating crohn's disease with anti-il23 specific antibody
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
JP7634474B2 (ja) 2018-07-18 2025-02-21 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
PL3883606T3 (pl) 2018-09-24 2023-11-27 Janssen Biotech, Inc. Bezpieczny i skuteczny sposób leczenia wrzodziejącego zapalenia jelita grubego przeciwciałami anty-il12/il23
MX2021005905A (es) 2018-11-20 2021-06-23 Janssen Biotech Inc Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
JP2022514561A (ja) 2018-12-18 2022-02-14 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法
JP7689074B2 (ja) 2019-01-15 2025-06-05 ヤンセン バイオテツク，インコーポレーテツド 若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
CN113330031A (zh) 2019-01-23 2021-08-31 詹森生物科技公司 用于在治疗银屑病关节炎的方法中使用的抗tnf抗体组合物
WO2020183269A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2020183418A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
CN113840837A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
JP7635137B2 (ja) 2019-03-14 2025-02-25 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための方法
AU2020243588C1 (en) 2019-03-18 2026-04-02 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-IL12/IL23 antibody
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
KR20220030952A (ko) 2019-06-03 2022-03-11 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
CA3142665A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
JP2022536088A (ja) 2019-06-04 2022-08-12 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
JP2023524125A (ja) 2020-05-05 2023-06-08 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体によるクローン病の治療方法
MX2022014430A (es) 2020-05-21 2023-02-22 Janssen Biotech Inc Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.
CA3189402A1 (en) 2020-07-13 2022-01-20 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
WO2022024065A1 (en) 2020-07-30 2022-02-03 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
CA3212729A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
AU2022232007A1 (en) 2021-03-12 2023-10-26 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
WO2023281466A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
CN117957251A (zh) 2021-07-09 2024-04-30 詹森生物科技公司 用于制备抗tnf抗体组合物的制造方法
CN118139883A (zh) 2021-07-09 2024-06-04 詹森生物科技公司 用于生产抗tnf抗体组合物的制造方法
AU2022374890A1 (en) 2021-10-29 2024-06-13 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CA3238377A1 (en) 2021-11-15 2023-05-19 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
CA3258517A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. TREATMENT METHOD FOR MILD TO MODERATE PSORIASIS WITH A SPECIFIC IL-23 ANTIBODY
KR20250011938A (ko) 2022-05-18 2025-01-22 얀센 바이오테크 인코포레이티드 Il23 항체에 의해 건선성 관절염을 평가 및 치료하기 위한 방법
JP2025539830A (ja) 2022-11-22 2025-12-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で潰瘍性大腸炎を治療する方法
CA3249015A1 (en) 2024-03-20 2025-10-31 Janssen Biotech, Inc. Methods of treating crohn’s disease with anti-il23 specific antibody
WO2025262604A1 (en) 2024-06-17 2025-12-26 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CA3258952A1 (en) 2024-06-27 2026-03-01 Janssen Biotech, Inc. Methods of treating ulcerative colitis with anti-il23 specific antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0614989A1 (en) * 1993-02-17 1994-09-14 MorphoSys AG A method for in vivo selection of ligand-binding proteins

Also Published As

Publication number Publication date
DE69417446T2 (de) 1999-09-02
EP0739413A1 (en) 1996-10-30
JPH09506000A (ja) 1997-06-17
CA2178205A1 (en) 1995-06-15
DE69417446D1 (de) 1999-04-29
EP0739413B1 (en) 1999-03-24
AU686292B2 (en) 1998-02-05
WO1995016027A1 (en) 1995-06-15
DK0739413T3 (da) 1999-10-11
AU1252195A (en) 1995-06-27
US5712089A (en) 1998-01-27
GR3030210T3 (en) 1999-08-31
JP3574135B2 (ja) 2004-10-06
ATE178092T1 (de) 1999-04-15
SE9304060D0 (sv) 1993-12-06

Similar Documents

Publication Publication Date Title
FI972390A0 (fi) Sytokiini nimeltä Lerk-7
DK0672063T3 (da) Mindste genkendelsesenhed af et PEM mucintandemgentagelsesspecifikt monoklonalt antistof
BRPI0314814B8 (pt) anticorpo compreendendo uma variante de fc
DK0739413T3 (da) Fremgangsmåde til udvælgelse af specifikke bakteriofager
AU5055593A (en) Antibodies specific for HIV
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
ES2072918T3 (es) Mejoras en la produccion de polipeptidos.
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
AU5243593A (en) Synthetic peptides, antibodies against them and their use
NO960349L (no) Immunanalyse for påvisning av kollagen eller kollagenfragmenter
IT7922812A0 (it) Dispositivo composito perl'esercizio positivo di segnaletica stradale, e metodo per la sua utilizzazione.
DE69033220D1 (de) Immunoassays für und monoklonale antikörper gegen prothrombin-aktivierende peptide und ihre abbauprodukte
ES2098159T3 (es) Bujia incandescente.
DK557289D0 (da) Monoklonalt, fucosylceramiderkendende antistof, dets fremstilling og anvendelse samt hybridoma til fremstillingen
ES2194012T3 (es) Epitopo p1a1 y p1a2 de la gpiii a de plaquetas, su preparacion y uso.
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
FI943218A7 (fi) Kaseinomakropeptidin peptidit, mainittujen peptidien vasta-aineet ja k äytöt
DE69434087D1 (de) ENTEROTOXINE VON SHIGELLA FLEXNERI 2a
ES2107545T3 (es) Anticuerpos policlonales dirigidos contra la hirudina y su utilizacion para la identificacion, la purificacion inmunologica y la determinacion cuantitativa de la hirudina.
FI971086A7 (fi) Kinaasia sitova proteiini ja sen käyttö
TR27897A (tr) Etanol ve izopropanol üretmeye mahsus yöntem.
WO1999019358A3 (de) Antikörper gegen baculoviren
EA199800028A1 (ru) Винилсульфоксиды и способы их синтеза
ATE256737T1 (de) Rekombinantes cdw52 antigen
SE0001138D0 (sv) Method and system for identification

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 739413

Country of ref document: ES